Scholars Central

EditorialPublished 2014

Revisiting Immunotherapy in Tuberculosis

Authors: Debapriya Bhattacharya, Ved Prakash Dwivedi, Gobardhan Das

Mycobacterial Diseases

Volume 4 · Issue 1 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The World Health Organization (WHO) estimates that one third of the global population is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), which is responsible for millions of death each year. Current therapy of TB consists of multiple expensive antibiotics and lengthy treatment, up to six months for drug-sensitive TB strains, and nine months to one year for drug-resistant TB strains. Therefore an alternative approach is urgently needed to fight this deadly disease. We propose immunotherapy which will enable to reduce length of treatment, toxic side effects, emergence of drug resistant variants, and prevent reactivation of the disease.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Mycobacterial Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMycobacterial Diseases
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Debapriya Bhattacharya”
  • BylineArticles whose byline prints “Ved Prakash Dwivedi”
  • BylineArticles whose byline prints “Gobardhan Das”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels